Morgan Stanley upgraded shares of Celgene Corporation (NASDAQ:CELG) from an underweight rating to an equal weight rating in a report published on Friday morning, MarketBeat.com reports.

Other analysts also recently issued research reports about the stock. BTIG Research downgraded shares of Celgene Corporation from a buy rating to a neutral rating and raised their price objective for the stock from $96.93 to $131.70 in a research report on Friday, June 30th. Vetr raised shares of Celgene Corporation from a buy rating to a strong-buy rating and set a $148.32 price objective for the company in a research report on Thursday, August 10th. UBS AG downgraded shares of Celgene Corporation from a strong-buy rating to a market perform rating and set a $160.00 price objective for the company. in a research report on Thursday, October 26th. SunTrust Banks, Inc. set a $150.00 price objective on shares of Celgene Corporation and gave the stock a buy rating in a research report on Thursday, July 6th. Finally, Canaccord Genuity set a $156.00 price target on shares of Celgene Corporation and gave the company a buy rating in a research report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the company. Celgene Corporation has an average rating of Buy and a consensus target price of $139.64.

Celgene Corporation (NASDAQ:CELG) opened at 100.97 on Friday. The stock has a 50 day moving average of $135.78 and a 200 day moving average of $129.85. The firm has a market cap of $78.99 billion, a PE ratio of 31.27 and a beta of 1.89. Celgene Corporation has a 12-month low of $94.55 and a 12-month high of $147.17.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.58 EPS. On average, equities research analysts anticipate that Celgene Corporation will post $7.32 EPS for the current fiscal year.

WARNING: “Celgene Corporation (CELG) Upgraded by Morgan Stanley to Equal Weight” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://theolympiareport.com/2017/10/31/celgene-corporation-celg-upgraded-by-morgan-stanley-to-equal-weight.html.

In other news, Director Ernest Mario sold 18,506 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the sale, the director now directly owns 69,424 shares in the company, valued at $9,061,220.48. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the sale, the insider now owns 3,925 shares in the company, valued at $564,768.25. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,233 shares of company stock worth $6,268,259. Company insiders own 0.95% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Arcadia Investment Management Corp MI increased its position in shares of Celgene Corporation by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares during the period. Thompson Davis & CO. Inc. increased its position in shares of Celgene Corporation by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares during the period. Guidant Wealth Advisors bought a new stake in shares of Celgene Corporation during the third quarter valued at about $119,000. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Celgene Corporation during the first quarter valued at about $118,000. Finally, Motco increased its position in shares of Celgene Corporation by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 159 shares during the period. Hedge funds and other institutional investors own 79.39% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.